Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency

Por Haddad, Elie, Berger, Melvin, Wang, Edward C. Y., Jones, Christopher A., Bexon, Martin, Baggish, Jeffrey S.
Publicado em 2011

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases

Por Kanegane, Hirokazu, Imai, Kohsuke, Yamada, Masafumi, Takada, Hidetoshi, Ariga, Tadashi, Bexon, Martin, Rojavin, Mikhail, Hu, Wilson, Kobayashi, Midori, Lawo, John-Philip, Nonoyama, Shigeaki, Hara, Toshiro, Miyawaki, Toshio
Publicado em 2014

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency

Por Tortorici, Michael A., Rogers, James A., Vit, Oliver, Bexon, Martin, Sandhaus, Robert A., Burdon, Jonathan, Chorostowska‐Wynimko, Joanna, Thompson, Philip, Stocks, James, McElvaney, Noel G., Chapman, Kenneth R., Edelman, Jonathan M.
Publicado no Br J Clin Pharmacol (2017)

ATIM-16. MRI-GUIDED CONVECTIVE DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA

Por Bankiewicz, Krystof, Achrol, Achal, Aghi, Manish, Bexon, Martin, Brenner, Andrew, Butowski, Nicholas, Elder, Bradley, Floyd, John, Lonser, Russell, Merchant, Fahar, Rosemina, Merchant, Patel, Toral R, Randazzo, Dina, Souweidane, Mark, Vogelbaum, Michael, Vrionis, Frank D, Sampson, John
Publicado no Neuro Oncol (2017)